| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| GTO ID | GTC0489 |
| Trial ID | NCT03975907 |
| Disease | Multiple Myeloma |
| Altered gene | BCMA |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CT053|zevorcabtagene autoleucel|zevor-cel |
| Location approved | China |
| Generation | 2nd |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1) |
| Year | 2019 |
| Country | China |
| Company sponsor | CARsgen Therapeutics Co., Ltd. |
| Other ID(s) | CT053-MM-01 |
| Cohort 1 | |||||||||||||||||||
|
|||||||||||||||||||